(Total Views: 582)
Posted On: 09/05/2020 6:06:31 PM
Post# of 153963
Re: thriftycents #54174
Thanks for the reply. We are all trying to learn here, so appreciate it. Sounds like your notes say two things. (1) Maraviroc somehow activates some immune function of CCR5 but LL does not. (2) Maraviroc blocks CCL3 and CCL4 binding to CCR5 but LL does not. Would be interested to read or hear more if you can find the sources. They both could explain maraviroc toxicity.
Speaking of maraviroc, preclinical study is out showing presumably nonCCR5 related antiviral function against SARS2.
https://www.biorxiv.org/content/10.1101/2020....389v1.full
Maraviroc has been used anecdotally with decent results and it will be interesting to see how the Covid trials with it go.
Don't think the researchers studied LL in vitro unfortunately.
Speaking of maraviroc, preclinical study is out showing presumably nonCCR5 related antiviral function against SARS2.
https://www.biorxiv.org/content/10.1101/2020....389v1.full
Maraviroc has been used anecdotally with decent results and it will be interesting to see how the Covid trials with it go.
Don't think the researchers studied LL in vitro unfortunately.
(2)
(0)
